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Intra-abdominal fat is an established risk factor for the metabolic syndrome. In this issue of Cell Metabolism,
Tran et al. (2008) test the cell-autonomous and location-related properties of transplanted intra-abdominal
and subcutaneous fat depots. While subcutaneous fat seems to confer metabolic benefits, species differ-
ences in adipose biology justify caution in interpreting the results.The presence of intra-abdominal fat is an
established risk factor for the metabolic
syndrome in humans (Klein et al., 2007).
Possible mechanisms include: (1) excess
fat and associated metabolites, peptides,
and hormones exert physiological conse-
quences via the portal circulation draining
to the liver; (2) cell-autonomous charac-
teristics of adipocytes and/or other cells
in the intra-abdominal depot that are inde-
pendent of their anatomic location, per se;
(3) increased intra-abdominal fat primarily
reflects physiological stress, which is the
proximate cause for the associated mor-
bidities; and (4) limited capacity of subcu-
taneous depots results in deposition of
excess fat in abdominal depots as well
as ‘‘ectopic’’ sites such as liver, muscle,
and islets. Deposition in the latter sites is
the proximate cause of associated mor-
bidities (Heilbronn et al., 2004). These
four possibilities are not mutually exclu-
sive (Klein et al., 2007).
In this issue, Tran et al. (2008) use fat
transplantation (see Figure 1) to test the
second hypothesis listed above. The
authors conclude that fat depots do have
cell-autonomous effects, with trans-
planted subcutaneous inguinal fat—but
not intra-abdominal (epididymal) fat—
conferring metabolic benefits. These
results are consistent with, and extend,
a recent report by Hocking et al.
(2008).
Tran et al. (2008) transplanted as much
as 1 g of fat (approximately 20% of final
recipient body fat) either intraperitoneally
or subcutaneously in mice, whereas
Hocking et al. (2008) transplanted 300mg;
both procedures produced similar effects
in the recipient. Between 10 and 12
weeks after receiving the transplants,mice with inguinal fat placed in the perito-
neal cavity had less body fat and were
more insulin sensitive than mice sub-
jected to sham surgery. Subcutaneous
placement of inguinal fat also affected re-
cipient phenotypes in the same direction,
but to a smaller degree than inguinal fat in
the abdominal cavity. In contrast, epididy-
mal fat transplanted either intraperitone-
ally or subcutaneously had no effect on
body fat mass or insulin sensitivity of
recipient mice.
Two tentative conclusions might be
drawn from these studies. (1) Metabolic
risk associated with intra-abdominal fat
deposition is determined at least in part
by cell-autonomous characteristics of
the transplanted tissue and not by the
total amount of fat present, because
addition of 1 g of inguinal fat increased
insulin sensitivity whereas 1 g of epididy-
mal fat did not. (2) Anatomically distinct
fat depots are phenotypically distinct (in
terms of adipocyte size and metabolic
and endocrine function) due to inherent
cellular characteristics rather than be-
cause of differences in neural and/or
blood supply to individual fat depots. A
tempting extrapolation is that accumula-
tion of subcutaneous fat is associated
with lower metabolic risk than accumula-
tion of visceral fat is, consistent with the
fourth hypothesis above and a recent
report of improved glucose tolerance in
adiponectin-overexpressing mice that
experience large increases in subcuta-
neous and pericardial fat (Kim et al.,
2007).
Caution is in order for a number of rea-
sons. First, experimental conditions may
influence apparent effects. For example,
mice receiving intraperitoneal epididymalCell Metabfat transplants are more insulin sensitive
than their controls when fasting, but not
when fed (Konrad et al., 2007). A second,
critical issue is the functional and ana-
tomic comparability of human and rodent
fat depots. A large proportion of human
intra-abdominal (‘‘visceral’’) fat is omen-
tal, a depot that is insignificant in ro-
dents. The fat depots that drain into the
portal circulation probably contribute
most significantly to metabolic risk,
though this notion has been challenged
(Miles and Jensen, 2005). By these func-
tional criteria, transplanted epididymal
fat attached to the abdominal wall (Hock-
ing et al., 2008) or interspersed within
endogenous epididymal fat (Tran et al.,
2008), would not be considered ‘‘vis-
ceral’’ fat both because of the anatomic
provenance of the tissue and because
of the drainage of metabolic and endo-
crine secretions into the systemic
circulation. Epididymal fat has no precise
human correspondent. Moreover, accu-
mulating evidence suggests that epididy-
mal fat does not respond to metabolic
processes as other fat depots do. For
example, epididymal fat does not in-
crease in obese chronically decerebrate
rats (Harris et al., 2006) or decrease dur-
ing a short period of starvation. Trans-
planting fat from a portal depot might
produce very different effects from those
seen with epididymal fat. In particular, an
interesting experiment would be trans-
plantation of human omental and subcu-
taneous fat into nude mice. Finally, the
transplantation of adipose tissue con-
veys cells other than adipocytes—e.g.,
resident macrophages—into the recipi-
ent animal (Weisberg et al., 2003). Tran
et al. (2008) did monitor macrophageolism 7, May 2008 ª2008 Elsevier Inc. 359
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PreviewsFigure 1. Schematic of Adipose Tissue Transplants
While the transplantation of epididymal (intra-abdominal) fat to either a subcutaneous or intra-abdominal depot (A and B) has little or no effect on body weight/fat
gain and hepatic gluconeogenesis, transplantation of inguinal (subcutaneous) adipose tissue to either an intra-abdominal or subcutaneous depot (C and D) im-
proves both parameters. The effect is greater for transplants to the intra-abdominal space. Prevailing notions of metabolic toxicity of intra-abdominal fat might
have predicted that transplants of intra-abdominal adipose tissue, especially into the intra-abdominal depot, would result in increased body fat and deranged
glucose homeostasis. The actual results aremore consistent with the principle that expanding subcutaneous fat depots can defend against ectopic fat deposition
and its adverse consequences in liver, muscle, and islets (Kim et al., 2007). Any extrapolation of these results to humans, however, should be made very cau-
tiously (see text). Figure by Elizabeth Watson (Columbia University).phenotypes, but depot differences in
these cells may be more striking in hu-
mans than in mice because obese
human subjects have twice as many
macrophages in omental fat as in subcu-
taneous fat (Cancello et al., 2006).
A question unanswered by the studies
of Tran et al. (2008) is the mechanism or
mechanisms by which intraperitoneally
transplanted inguinal fat modifies total
fat mass and insulin sensitivity of mice.
Surprisingly, food intake and energy ex-
penditure were not different between the
mice receiving intraperitoneal inguinal
transplants and their sham controls. Yet
some change in energy balance must ac-
count for the difference in weight gain ob-
served between 8 and 12 weeks after fat
transplantation. A 5 g difference in fat ac-
cumulation over a period of 4 weeks cor-
responds to an energy imbalance of ap-
proximately 267 kJ (Pullar and Webster,
1977), or 9.5 kJ/day; undetected small
changes in energy expenditure and/or in-
take may account for the observed differ-
ences. Also surprising was the finding that
respiratory quotient was higher in the
mice that gained the least weight, indicat-
ing a preference for carbohydrate over fat
oxidation. The changes in insulin sensitiv-360 Cell Metabolism 7, May 2008 ª2008 Elsity in mice with inguinal transplants were
attributed to a dramatic inhibition of liver
gluconeogenesis. Circulating factors
and/or neural systems may modulate
this apparent regulation of liver metabo-
lism by adipose tissue. The decreased
adipose adiponectin mRNA levels in the
mice with improved insulin responsive-
ness argue against the involvement of
this peptide (Pajvani et al., 2003), but the
decline in resistin expression could po-
tentially contribute to improved hepatic
insulin sensitivity (Rajala et al., 2003).
Whatever the identity of the fat-derived
signal, it is induced in the transplant over
time, because the 50% difference in fat
content of mice with intraperitoneal ingui-
nal transplants comparedwith other treat-
ment groups was present at 12 weeks,
but not at 8 weeks, after surgery.
Tran et al. (2008) have provided new
evidence for cell-autonomous metabolic
phenotypes of adipose tissue from ana-
tomically distinct sites, with the tantalizing
suggestion that accumulation of fat in
subcutaneous fat depots confers meta-
bolic benefits. These observations are
consistent with the idea that expansion
of subcutaneous depots can protect
against ectopic deposition of excessevier Inc.lipids in liver, muscle, and other organs
adversely affected in obesity (Klein et al.,
2007; Kim et al., 2007). The increased ef-
ficacy of subcutaneous adipose tissue in
the intra-abdominal space raises impor-
tant questions regarding prevailing no-
tions of primacy of position over prove-
nance and the metabolic consequences
of excess adipose tissue.
REFERENCES
Cancello, R., Tordjman, J., Poitou, C., Guilhem, G.,
Bouillot, J.L., Hugol, D., Coussieu, C., Basdevant,
A., Bar Hen, A., Bedossa, P., et al. (2006). Diabetes
55, 1554–1561.
Harris, R.B., Kelso, E.W., Flatt, W.P., Bartness,
T.J., and Grill, H.J. (2006). Endocrinology 147,
1365–1376.
Heilbronn, L., Smith, S.R., and Ravussin, E. (2004).
Int. J. Obes. Relat. Metab. Disord. 28 (Suppl 4),
S12–S21.
Hocking, S.L., Chisholm, D.J., and James, D.E.
(2008). Diabetologia 51, 900–902.
Kim, J.Y., van de Wall, E., Laplante, M., Azzara, A.,
Trujillo, M.E., Hofmann, S.M., Schraw, T., Durand,
J.L., Li, H., Li, G., et al. (2007). J. Clin. Invest. 117,
2621–2637.
Klein, S., Allison, D.B., Heymsfield, S.B., Kelley,
D.E., Leibel, R.L., Nonas, C., and Kahn, R. (2007).
Diabetes Care 30, 1647–1652.
Cell Metabolism
PreviewsKonrad, D., Rudich, A., and Schoenle, E.J. (2007).
Diabetologia 50, 833–839.
Miles, J.M., and Jensen, M.D. (2005). Diabetes
Care 28, 2326–2328.
Pajvani, U.B., Du, X., Combs, T.P., Berg, A.H.,
Rajala, M.W., Schulthess, T., Engel, J., Brownlee,
M., and Scherer, P.E. (2003). J. Biol. Chem. 278,The CAMplexities
Mark W. Sleeman1,* and Esther Latres1
1Regeneron Pharmaceuticals, Inc., Tarrytown
*Correspondence: mark.sleeman@regeneron
DOI 10.1016/j.cmet.2008.04.009
The gut hormone ghrelin is known
energy balance. In this issue of Ce
effect by forming a unique comple
from the more established AMP/LK
Over the last decade, attention has been
focused on elucidating the role of the cen-
tral nervous system (CNS) in the regula-
tion of appetite, energy expenditure, and
metabolism. Combined genetic and phar-
macological manipulations have clearly
defined a number of critical neural popu-
lations, signaling steps, and pathways,
and the associated cellular events are
now being elucidated. A central player is
the adipose-specific protein leptin, which
is secreted in conditions of nutrient ex-
cess and is thought to act at least in part
on the neurons within the arcuate nucleus
(ARC) and the ventromedial hypothala-
mus to modulate the expression of neuro-
peptides such as neuropeptide Y (NPY),
agouti-related peptide (AgRP), and a-
melanocyte-stimulating hormone (aMSH)
to regulate food intake and metabolic
events. More recently, the orexigenic (food
intake-promoting) gut-derived peptide
ghrelin has been shown to impact many of
the same pathways. The opposing actions
of leptin and ghrelin converge within the
basal hypothalamus on the AMP-activated
protein kinase (AMPK) system, a highly
conserved sensor of cellular energy status
present in all eukaryotic cells.
AMPK exists as a heterotrimeric com-
plex of the catalytic a subunit and regula-
tory b and g subunits that responds to
a change in the AMP/ATP ratio. The sub-9073–9085. Published online December 20, 2002.
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to activate hypothalamic AMPK, a c
ll Metabolism, Anderson et al. (2008
x of AMPKa/b with acetyl-CoA carbo
B1 pathway.
sequent rise in AMP results in the alloste-
ric activation of AMPK, but it is also known
to facilitate the phosphorylation of AMPK
by the upstream kinase LKB1. In vitro
studies of cells lacking LKB1 also have
shown a basal phosphorylation and
activity of AMPK, indicating the presence
of an additional upstream kinase. This
was identified as the Ca2+/calmodulin
(CaM)-dependent protein kinase kinase
(CaMKK; Hawley et al., 2005). In this is-
sue, Anderson et al. (2008) demonstrate
an in vivo role for CaMKK2 in regulating
hypothalamic AMPK activity.
Some of the first evidence for physio-
logical activation of the AMPK system
came from studies that reported leptin-
dependent activation of the a2 isoform
of AMPK in skeletal muscle (Minokoshi
et al., 2002). More importantly for this dis-
cussion, hormones (e.g., leptin and insu-
lin) and nutrients (e.g., glucose) have
been demonstrated to inhibit AMPKa2
activity in the hypothalamus, an effect
that correlates with the behavioral actions
of central leptin, insulin, and glucose to
inhibit food intake (Kahn et al., 2005).
Many separate biochemical studies have
now elucidated some specific substrates
for AMPK (Towler and Hardie, 2007) that
contributed to placing the AMPK pathway
in a more physiological context (Pocai
et al., 2006). Leptin, through activation of
Cell MetaTran, T.T., Yamamoto, Y., Gesta, S., and Kahn,
C.R. (2008). Cell Metab. 7, this issue,
410–420.
Weisberg, S.P., McCann, D., Desai, M., Rose-
nbaum, M., Leibel, R.L., and Ferrante, A.W., Jr.
(2003). J. Clin. Invest. 112, 1796–1808.rucial metabolic sensor controlling
) show that CaMKK2 mediates this
xylase (ACC) in a pathway distinct
central receptors within the ARC, leads
to reducedactivationofAMPK, aconcom-
itant increase in activity of acetyl-CoA
carboxylase (ACC), and increased for-
mation of malonyl-CoA. As malonyl-CoA
is a key regulator of the mitochondrial
enzyme carnitine palmitoyltransferase
(CPT-1), this ultimately results in an in-
crease in metabolic flux in the fatty acid
synthesis pathway and decreased b-oxi-
dation. Despite these advances, the exact
mechanisms by which leptin decreases
the activity of AMPK remain unknown,
with their elucidation perhaps compli-
cated by the multiplicity of signaling
events emanating from activation of the
leptin receptor (including PI3K, STAT2,
MAPK, and Ca2+; see Figure 1A).
CaMKK2 is expressed predominantly in
the CNS. The growth hormone secreta-
gogue receptor (GHS-R) is known to be
coupled toGq (thereby activating intracel-
lular Ca2+). Means and colleagues (Ander-
son et al., 2008) therefore postulated that
the recently described actions of ghrelin
to activate hypothalamic AMPK (Ander-
sson et al., 2004) might be mediated
through CaMKK2. They tested this hy-
pothesis by generating and extensively
phenotyping CaMKK2 null mice.
Their detailed analysis of CaMKK2
expression in ARC punches of normal
mice revealed an up to 20-fold enrichment
bolism 7, May 2008 ª2008 Elsevier Inc. 361
